⌕
Organon · OGN · NYSE
Tenet 45 · Mixed
Compare
$13.900.00%At closeTenet 45 · Mixed
$13.900.00 (0.00%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD

Organon (OGN) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is OGN's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Business WireNov 12, 2026 · 10:00 ETCOMPANY'S OWN WORDS
Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA® (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI

JERSEY CITY, N.J.--(BUSINESS WIRE)--ACAAI- new pooled post-hoc analysis of VTAMA (tapinarof) cream, 1% demonstrates consistent response for atopic dermatitis disease severity and itch.…

OGN 0.0% todayRead at source ↗
● Zacks Investment ResearchNov 10, 2026 · 10:01 ET
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.…

OGN 0.0% todayRead at source ↗
● Defense WorldNov 3, 2026 · 03:45 ETEARNINGS EXPECTED BY FEB 16
Contrasting CASI Pharmaceuticals (NASDAQ:CASI) and Organon & Co. (NYSE:OGN)

Organon and Co. (NYSE: OGN - Get Free Report) and CASI Pharmaceuticals (NASDAQ: CASI - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strengt…

OGN 0.0% todayRead at source ↗
● Zacks Investment ResearchOct 30, 2026 · 10:31 ETEARNINGS EXPECTED BY FEB 16
Organon (OGN) Q3 Earnings and Revenues Top Estimates

Organon (OGN) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $1.01 per share a year ago.…

OGN 0.0% todayRead at source ↗
● Business WireOct 30, 2026 · 08:25 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Organon Announces Quarterly Dividend

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Announces Quarterly Dividend.…

OGN 0.0% todayRead at source ↗
● Zacks Investment ResearchOct 26, 2026 · 10:01 ET
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.…

OGN 0.0% todayRead at source ↗
● Business WireOct 19, 2026 · 07:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its third quarter 2026 financia…

OGN 0.0% todayRead at source ↗
● Defense WorldOct 17, 2026 · 03:29 ETEARNINGS EXPECTED BY FEB 16
Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS) Critical Comparison

Organon and Co. (NYSE: OGN - Get Free Report) and Xeris Biopharma (NASDAQ: XERS - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength…

OGN 0.0% todayRead at source ↗
● Business WireOct 16, 2026 · 07:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon reports positive interim Phase 3 results for MIUDELLA®, a hormone-free IUD, through 6 years of use with no new safety signals.…

OGN 0.0% todayRead at source ↗
● Zacks Investment ResearchOct 14, 2026 · 10:01 ET
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.…

OGN 0.0% todayRead at source ↗
● Zacks Investment ResearchOct 2, 2026 · 10:01 ET
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.…

OGN 0.0% todayRead at source ↗
● Business WireOct 1, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to unveil first large-scale real-world effectiveness analyses of VTAMA (tapinarof) cream, 1% in patients with eczema at Fall Clinical.…

OGN 0.0% todayRead at source ↗
● Zacks Investment ResearchSep 21, 2026 · 10:01 ET
Is Trending Stock Organon & Co. (OGN) a Buy Now?

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.…

OGN 0.0% todayRead at source ↗
● Defense WorldSep 15, 2026 · 04:02 ETEARNINGS EXPECTED BY FEB 16
VIRGINIA RETIREMENT SYSTEMS ET Al Makes New $770,000 Investment in Organon & Co. $OGN

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Organon and Co. (NYSE: OGN) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 56,850 shares of the compan…

OGN 0.0% todayRead at source ↗
● Business WireSep 14, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces FDA accepts MIUDELLA® sNDA for review, seeking to extend approved hormone-free IUD use from 3 to 6 years in the U.S.…

OGN 0.0% todayRead at source ↗
● Zacks Investment ResearchSep 8, 2026 · 10:01 ET
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.…

OGN 0.0% todayRead at source ↗
● Defense WorldAug 29, 2026 · 04:12 ETEARNINGS EXPECTED BY FEB 16
Bank of America Corp DE Has $4.42 Million Stock Position in Organon & Co. $OGN

Bank of America Corp DE reduced its position in shares of Organon and Co. (NYSE: OGN) by 58.5% in a recent quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 738,502 …

OGN 0.0% todayRead at source ↗
● GlobeNewsWireAug 27, 2026 · 09:00 ET
National Can-RISE Study to Help Close Critical Gaps in Menopause Research

TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Women's Health Collective Canada (WHCC) and the Partnership for Women's Health Research Canada (PWHR), in partnership with GreenShield and supported by a charitable grant from O…

OGN 0.0% todayRead at source ↗
● Defense WorldAug 25, 2026 · 03:47 ET
Organon & Co. (NYSE:OGN) Sets New 52-Week High – Still a Buy?

Organon and Co. (NYSE: OGN - Get Free Report) reached a new 52-week high during trading on Tuesday. The stock traded as high as $13.76 and last traded at $13.7540, with a volume of 4583387 shares trading hands. The stock…

OGN 0.0% todayRead at source ↗

Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just OGN · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.